This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignee: Novartis Ag. Active years: 2011-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hegenhein, FR (2013)
- Basel, CH (2011 - 2016)
Company Filing History:
Years Active: 2011-2016
Title: The Innovations of Christian Rene Schnell
Introduction
Christian Rene Schnell is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of short interfering ribonucleic acid (siRNA) for oral administration. With a total of 6 patents to his name, Schnell's work is paving the way for advancements in therapeutic applications.
Latest Patents
Schnell's latest patents focus on the formulation of siRNA for oral administration. These patents describe siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides. Each strand is 49 nucleotides or less, with at least one strand containing at least one chemical modification. This innovative approach has the potential to enhance the efficacy of RNA-based therapies.
Career Highlights
Christian Rene Schnell is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to explore and develop cutting-edge solutions in the field of RNA therapeutics. His expertise and innovative mindset have contributed to the company's research and development efforts.
Collaborations
Schnell has collaborated with esteemed colleagues such as Francois Jean-Charles Natt and Eric Billy. These collaborations have fostered a dynamic environment for innovation and have led to significant advancements in their respective fields.
Conclusion
Christian Rene Schnell's contributions to the field of biotechnology, particularly in the development of siRNA for oral administration, highlight his role as a leading inventor. His work continues to inspire advancements in therapeutic applications, making a lasting impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
